Abstract Library

#4175 Immunohistochemical profiling of lung carcinoid subtypes and marker comparison of matched primary and metastatic tumors

Introduction: Multi-omic studies have identified three lung carcinoid (LC) subtypes (A1, A2, B) with unique gene expression for OTP, ASCL1 & HNF1a.

Conference:

Presenting Author: Leunissen D

Authors: Leunissen D, Moonen L, von der Thüsen J, den Bakker M, Hillen L,

Keywords: lung carcinoid, TTF1, S100, metastatic disease,

#4120 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): An international case series

Introduction: Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) is a rare disorder that is characterized by diffuse hyperplasia of bronchiolar and bronchial pulmonary neuroendocrine cells. The precise incidence and prevalence is unknown and the clinical course is not fully understood.

Conference:

Presenting Author: Almeamar H

Authors: Penugonda M, O'Callaghan M, Diesler R, O'Brien H, Almeamar H,

Keywords: DIPNECH, NET, neuroendocrine, pulmonary NET, Neuroendocrine cells hyperplasia,

#3963 Infrastructure FOr Rare Cancer in the NEtherlands, towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE), and especially neuroendocrine neoplasms (NEN)

Introduction: NEN consist of a heterogeneous group of rare tumors. For these patients, clinical trials requiring a high number of patients are often infeasible. Often, the prognosis is poor due to late diagnosis and fewer available treatment options as compared to patients with common cancer types. In common cancers, ultrasensitive molecular profiling of circulating cell-free DNA (USccfDNA) based tests are promising to improve diagnosis, detection of minimal residual disease (MRD), and recurrence. Data needed to apply USccfDNA in NEN is lacking.

Conference:

Presenting Author:

Authors: de Hosson L, Pieterman C, Fehrmann R, de Herder W, Jalving M,

Keywords: circulating cell free DNA, biobank, databank, early detection,

#3886 Large cell neuroendocrine carcinoma subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression

Introduction: Large cell neuroendocrine carcinoma (LCNEC) accounts for 1-3% of all types of lung cancer and is, similar to small-cell lung cancer (SCLC), a high-grade tumor with poor prognosis. pRb can also be used to subclassify LCNEC into SCLC-like and NSCLC-like. SCLC can be classified in 4 transcriptomic subtypes (NEUROD1high, ASCL1high, POU2F3high, YAP1high), which may have therapeutic implications. It is unclear whether these subtypes are also found in LCNEC and if they correlate with pRb expression.

Conference:

Presenting Author: Heijboer F

Authors: Rijnsburger N, Heijboer F, Derks J, Hermans B, Hillen L,

Keywords: LCNEC, pulmonary, immunohistochemistry, pathology, pRb, transcription factors,

#3863 Survival and prognostic factors in appendiceal neuroendocrine tumors (ANET) and goblet cell carcinoma (aGCC)

Introduction: Appendiceal goblet cell carcinomas (aGCC) present with overlapping features of appendiceal neuroendocrine neoplasms (ANET) and adenocarcinomas. A previous study found that ANET with peritoneal metastases have a 5-year survival rate of 7%. Recent studies show that ANET rarely metastasizes, contrary to aGCC. The latest WHO classification excluded aGCC from the group of NETs and classified it as appendiceal adenocarcinomas.

Conference:

Presenting Author: Dijke K

Authors: Dijke K, Levy S, van den Berg J, Tesselaar M,

Keywords: Goblet cell carcinoma, Appendiceal neuroendocrine tumor, Survival,